FDA Clears Andrew Technologies’ Autologous Fat Transfer Project
There was some great news recently for Andrew Technologies, as their Autologous Fat Transfer project received green signal from the US FDA division. US FDA has granted the project with a sum of USD 510,000.
This project involves reinjection of the adipose tissue, which gets harvested during HydraSolve Liposuction Treatments, into the same patient for augmentation and rejuvenation. Till date, there has been no liposuction device, which received FDA clearance for such usage.
Andrew Technologies’ chief scientific officer, Dr Mark S Andrew, said that they are quite happy to be the first to provide the autologous fat grafting technology. According to him, this can help the surgical process. At the same time, the patient will also receive better outcomes with this technology.
Indianapolis Plastic Surgeon, Dr Bruce Van Natta, is playing a major role in the HydraSolve’s Expert Release Program. He has treated numerous patients for the past two months. He finds HydraSolve to be one of the few procedures, which can remove fat at a rapid pace. Almost bloodless fat tissues are gathered during the procedure, which can easily get re-injected back into breasts as well as other target regions. For Dr Bruce, this has been the best autologous fat grafting system, which he has come across in his lifetime.
Andrew Technologies’ CEO, Tom Albright, was also thrilled with the news of achieving their second FDA clearance in a matter of 6 months. Since it is a startup company, for Tom, it was an amazing accomplishment.
For some time, autologous fat grafting has been a major focus of aesthetic medicine. With Andrew Technologies’ innovative product, surgeons will get the first liposuction device, which has received FDA clearance, for harvesting adipose tissue and this is a big step for the progress of Fat Grafting.